Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Mayne Pharma Group ( (AU:MYX) ).
UBS Group AG and its related bodies corporate have ceased to be substantial shareholders of Mayne Pharma Group Limited as of October 16, 2025. This change in shareholder status may impact Mayne Pharma’s market dynamics and investor relations, as substantial shareholders often have significant influence over company decisions.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$6.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
YTD Price Performance: 24.55%
Average Trading Volume: 354,323
Technical Sentiment Signal: Buy
Current Market Cap: A$502.9M
See more insights into MYX stock on TipRanks’ Stock Analysis page.